
Read more from our scientific experts and subject matter experts
At Cerba we believe that we are stronger together and that we can grow together. Discover how we are growing and learning first hand with the latest news from Cerba Research!

Cerba Research is officially a member of Hong Kong Bio-Med Innotech Association (HKBMIA)
Ghent, Belgium, 11 January 2023 Cerba Research announces membership of HKBMIA as…
Read more

CerbACT Asia receives CAP Certification
Cerba Research is happy to announce that our CerbACT lab in Taiwan…
Read more

Cerba Healthcare releases 2021/2022 CSR Report
Recently Cerba Research has released its CSR Report for 2021/2022. At Cerba…
Read more

In Light of NASH: Liver Biopsy Optimization Webinar
Liver biopsies are the gold standard for Non-Alcoholic Steatohepatitis diagnosis and thus…
Read more

Webinar: Turning Precision Medicine into Action in Immuno-Oncology
The challenges in immuno-oncology (I/O) drug development require deep scientific insights, generation…
Read more

The Merger of Cerba Research and Viroclinics-DDL
Together, transforming diagnostics for clinical trials After the acquisition of Viroclinics-DDL by…
Read more

Challenges of Covid-19 Testing: Which Test to Use?
Are you using the right Covid-19 test? In the race to contain…
Read more

Analyzing Multiple Biomarkers with IHC: putting a 6-plex kit to the challenge
On November 16, 2021 Cerba Research and Akoya Biosciences held a webinar…
Read more

Spotlight on Ramdane Mallek – Genomics & NGS Lab Manager at Cerba Lab
Watch this short video and discover:
Read more

Spotlight on Adrien Ko – Medical Advisor at Cerba Research
Watch this short video and discover: How Cerba Research is connecting real…
Read more

Turning Precision Medicine into Action in Immuno-Oncology
The challenges in immuno-oncology (I/O) drug development require deep scientific insights, generation…
Read more

A Biomarker Journey in Immuno-Oncology Utilizing Immunohistochemistry
In immuno-oncology (IO) research, biomarkers present the opportunity to identify and target…
Read more